Author Index Volume 56 (2017)
The issue number is given in front of the pagination
Aarsland, D., see Bergland, A.K. (2) 575–584
Aarsland, D., see Chong, J.R. (1) 157–166
Abrescia, P., see Benussi, L. (2) 825–833
Adolfsson, O., see Theunis, C. (2) 585–599
Agüera-Ortiz, L., see Ismail, Z. (3) 929–938
Agyemang, C., I.E. van de Vorst, H.L. Koek, M.L. Bots, A. Seixas, M. Norredam, U. Ikram, K. Stronks and I. Vaartjes, Ethnic Variations in Prognosis of Patients with Dementia: A Prospective Nationwide Registry Linkage Study in The Netherlands (1) 205–213
Ahmed, M.E., see Lu, Y. (4) 1469–1484
Ahonen, R., see Koponen, M. (1) 107–118
Aisen, P.S., see Sokolow, S. (1) 229–237
Aizenstein, O., see Molad, J. (4) 1293–1299
Akatsu, H., see Sabbagh, M.N. (2) 441–446
Akazawa, K., see Kuriyama, N. (4) 1253–1262
Akiba, C., see Jurjević, I. (1) 317–325
Alcolea, D., see Tell-Marti, G. (3) 1065–1074
Alegret, M., see Boada, M. (1) 129–143
Allen, M., see N’Songo, A. (4) 1215–1222
Almkvist, O., see Li, X. (1) 327–334
Alperin, N., see Loewenstein, D.A. (3) 1119–1126
Ambrosi, A., ses Ferrari, L. (3) 1101–1107
Amen, D.G., B. Darmal, C.A. Raji, W. Bao, L. Jorandby, S. Meysami and C.S. Raghavendra, Discriminative Properties of Hippocampal Hypoperfusion in Marijuana Users Compared to Healthy Controls: Implications for Marijuana Administration in Alzheimer’s Dementia (1) 261–273
Amenta, F., see Carotenuto, A. (2) 805–815
Amin, N.D., see Shukla, V. (1) 335–349
An, H., see Kim, Y.J. (3) 1007–1014
Anand, K., see Sabbagh, M.N. (2) 441–446
Anaya, F., see Boada, M. (1) 129–143
Angus, J.A., see Betrie, A.H. (2) 849–860
Anstey, K.J., K. Ashby-Mitchell and R. Peters, Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis (1) 215–228
Antonell, A., see Tell-Marti, G. (3) 1065–1074
Apostolova, I., C. Lange, A. Roberts, H.J. Igel, A. Mäurer, S. Liese, M. Estrella, V. Prasad, E. Stechl, G. Lämmler, E. Steinhagen-Thiessen and R. Buchert, Challenges in Screening and Recruitment for a Neuroimaging Study in Cognitively Impaired Geriatric Inpatients (1) 197–204
Apostolova, L.G., see Sokolow, S. (1) 229–237
Arai, H., see Jurjević, I. (1) 317–325
Araujo, J.A., see Borghys, H. (2) 763–774
Archetti, S., see Ferrari, R. (4) 1271–1278
Arighi, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Arnold, S.E., see Yarchoan, M. (2) 699–706
Artyuhov, A.S., see Dashinimaev, E.B. (2) 835–847
Arvanitakis, Z., see Yarchoan, M. (2) 699–706
Ashby-Mitchell, K., see Anstey, K.J. (1) 215–228
Ashe, K.H., see Liu, P. (2) 743–761
Asmann, Y., see N’Songo, A. (4) 1215–1222
Asthana, S., see Law, L.L. (1) 351–359
Attems, J., see Chong, J.R. (1) 157–166
Audoin, B., see Sellal, F. (1) 37–46
Auger, L.E., see Last, N. (1) 275–286
Auriel, E., see Molad, J. (4) 1293–1299
Avila, J., see Gomez-Ramos, A. (3) 977–990
Axmacher, N., see Kunz, L. (3) 1135–1144
Ayres, A., see Valenti, R. (4) 1223–1227
Ayton, S., see Betrie, A.H. (2) 849–860
Baazaoui, N., M. Flory and K. Iqbal, Synaptic Compensation as a Probable Cause of Prolonged Mild Cognitive Impairment in Alzheimer’s Disease: Implications from a Transgenic Mouse Model of the Disease (4) 1385–1401
Bäckman, L., see Khan, W. (3) 1159–1174
Badenas, C., see Tell-Marti, G. (3) 1065–1074
Bagnoli, S., see Ferrari, R. (4) 1271–1278
Bai, F., see Su, F. (2) 491–507
Baldeiras, I., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Ballard, C.G., see Chong, J.R. (1) 157–166
Banaschewski, T., see Khan, W. (3) 1159–1174
Bao, W., see Amen, D.G. (1) 261–273
Barão, S., see Timmers, M. (4) 1437–1449
Barcs, G., see Horváth, A. (3) 1175–1183
Barker, G.J., see Khan, W. (3) 1159–1174
Barkhof, F., see Louwersheimer, E. (1) 63–74
Baroni, M., see Boccardi, V. (1) 239–248
Barrett, M.S., see Siegel, A.M.
Barrio, J.R., see Doran, E. (2) 459–470
Barthel, H., see Sabbagh, M.N. (2) 441–446
Bastian, F.O., Combined Creutzfeldt-Jakob/Alzheimer’s Disease Cases are Important in Search for Microbes in Alzheimer’s Disease (3) 867–876
Batchelor, J., see McKinnon, A.C. (4) 1373–1384
Bautz, A., see Thygesen, L.C. (4) 1429–1435
Behrens, T.W., see Haddick, P.C.G. (3) 1037–1054
Belliard, S., see Gaubert, M. (2) 717–731
Ben Assayag, E., see Molad, J. (4) 1293–1299
Ben Bashat, D., see Molad, J. (4) 1293–1299
Bendlin, B.B., see Law, L.L. (1) 351–359
Benedí, J., see González-Muñoz, M.J. (3) 917–927
Bennett, D.A., see Yarchoan, M. (2) 699–706
Bennett, D.A., see Yu, L. (4) 1485–1493
Benussi, L., R. Ghidoni, F.D. Piaz, G. Binetti, G. Di Iorio and P. Abrescia, The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer’s Disease (2) 825–833
Benussi, L., see Ferrari, R. (4) 1271–1278
Bergland, A.K., I. Dalen, A.I. Larsen, D. Aarsland and H. Soennesyn, Effect of Vascular Risk Factors on the Progression of Mild Alzheimer’s Disease and Lewy Body Dementia (2) 575–584
Bernardi, L., see Ferrari, R. (4) 1271–1278
Betrie, A.H., S. Ayton, A.I. Bush, J.A. Angus, P. Lei, C.E. Wright, Evidence of a Cardiovascular Function for Microtubule-Associated Protein Tau (2) 849–860
Bhangale, T.R., see Haddick, P.C.G. (3) 1037–1054
Bhati, M.T., see Siegel, A.M.
Biegon, A., see Sundermann, E.E. (3) 947–957
Bielarczyk, H., see Zyśk, M. (3) 1145–1158
Binetti, G., see Benussi, L. (2) 825–833
Binetti, G., see Ferrari, R. (4) 1271–1278
Binukumar, B.K., see Shukla, V. (1) 335–349
Blennow, K., see Li, X. (1) 327–334
Blennow, K., see Toombs, J. (3) 885–891
Blennow, K., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Blusztajn, J.K., see Wang, E. (1) 47–61
Boada, M., F. Anaya, P. Ortiz, J. Olazarán, J.R. Shua-Haim, T.O. Obisesan, I. Hernández, J. Muñoz, M. Buendia, M. Alegret, A. Lafuente, L. Tárraga, L. Núñez, M. Torres, J.R. Grifols, I. Ferrer, O.L. Lopez and A. Páez, Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial (1) 129–143
Boccardi, V., M. Baroni, N. Smirne, A. Clodomiro, S. Ercolani, A. Longo, C. Ruggiero, A.C. Bruni and P. Mecocci, Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer’s Disease: A “Real World” Study (1) 239–248
Bocti, C., see Castellano, C.-A. (4) 1459–1468
Boddaert, J., see Zerah, L. (1) 145–156
Bogert, J., see Timmers, M. (4) 1437–1449
Bohlken, J., see Jacob, L. (1) 379–384
Bohlken, J., see Jacob, L. (4) 1519–1524
Bokde,A.L.W., see Khan, W. (3) 1159–1174
Bolshakov, A.P., see Dashinimaev, E.B. (2) 835–847
Bondi, M.W., see Granholm, E.L. (4) 1419–1428
Bonomi, E., see Ferrari, R. (4) 1271–1278
Boots, E.A., see Law, L.L. (1) 351–359
Borchelt, D.R., see Liu, P. (2) 743–761
Borghgraef, P., see Theunis, C. (2) 585–599
Borghys, H., B. Van Broeck, D. Dhuyvetter, T. Jacobs, K. de Waepenaert, T. Erkens, M. Brooks, S. Thevarkunnel and J.A. Araujo, Young to Middle-Aged Dogs with High Amyloid-β Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests (2) 763–774
Bornstein, N.M., see Molad, J. (4) 1293–1299
Borroni, B., see Ferrari, R. (4) 1271–1278
Borsello, T., see Buccarello, L. (4) 1279–1292
Bots, M.L., see Agyemang, C. (1) 205–213
Boulouis, G., see Valenti, R. (4) 1223–1227
Bouwman, F.H., see Slot, R.E.R. (2) 687–697
Boyle, P.A., see Yu, L. (4) 1485–1493
Bozzali, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Brandscheid, C., F. Schuck, S. Reinhardt, K.-H. Schäfer, C.U. Pietrzik, M. Grimm, T. Hartmann, A. Schwiertz and K. Endres, Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer’s Mouse Model (2) 775–788
Brann, D., see Lu, Y. (4) 1469–1484
Bremer, J.A.E., see Van Mierlo, L.D. (1) 249–259
Brodaty, H., see Ismail, Z. (3) 929–938
Brooks, M., see Borghys, H. (2) 763–774
Brooks, S.W., A.C. Dykes and B.G. Schreurs, A High-Cholesterol Diet Increases 27-Hydroxycholesterol and Modifies Estrogen Receptor Expression and Neurodegeneration in Rabbit Hippocampus (1) 185–196
Bruce, D.G., see Peters, K.E. (3) 1127–1133
Bruni, A.C., see Boccardi, V. (1) 239–248
Bruni, A.C., see Ferrari, R. (4) 1271–1278
Buccarello, L., G. Grignaschi, A.M. Castaldo, A. Di Giancamillo, C. Domeneghini, R.C. Melcangi and T. Borsello, Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy (4) 1279–1292
Büchel, C., see Khan, W. (3) 1159–1174
Buchert, R., see Apostolova, I. (1) 197–204
Buendia, M., see Boada, M. (1) 129–143
Bush, A.I., see Betrie, A.H. (2) 849–860
Caga, J., see Kaizik, C. (3) 1109–1117
Cai, J., see Li, L. (4) 1403–1417
Caltagirone, C., see Gelfo, F. (4) 1505–1518
Calvo-Garrido, J., see Persson, T. (2) 601–617
Camino, J., see Kaizik, C. (3) 1109–1117
Campion, D., see Sellal, F. (1) 37–46
Caon, M., see Ienca, M. (4) 1301–1340
Capp, K., see Loewenstein, D.A. (3) 1119–1126
Carlsson, C.M., see Law, L.L. (1) 351–359
Carotenuto, A., R. Rea, E. Traini, A.M. Fasanaro, G. Ricci, V. Manzo and F. Amenta, The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer’s Disease: Interim Results of the ASCOMALVA Trial (2) 805–815
Carrasquillo, M.M., see N’Songo, A. (4) 1215–1222
Carter, A.Y., see Fitz, N.F. (3) 1075–1085
Casson, R.J., see Chidlow, G. (2) 655–675
Castagna, A., see Gareri, P. (2) 557–565
Castaldo, A.M., see Buccarello, L. (4) 1279–1292
Castellano, C.-A., N. Paquet, I.J. Dionne, H. Imbeault, F. Langlois, E. Croteau, S. Tremblay, M. Fortier, J.J. Matte, G. Lacombe, T. Fülöp, C. Bocti and S.C. Cunnane, A 3-Month Aerobic Training Program Improves Brain Energy Metabolism in Mild Alzheimer’s Disease: Preliminary Results from a Neuroimaging Study (4) 1459–1468
Castelo-Branco, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Castranio, E.L., see Fitz, N.F. (3) 1075–1085
Cavedo, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Cedazo-Mínguez, Á., see Persson, T. (2) 601–617
Chai, Y.L., see Chong, J.R. (1) 157–166
Chang, K.J., C.H. Hong, K.S. Lee, D.R. Kang, J.D. Lee, S.H. Choi, S.Y. Kim, D.L. Na, S.W. Seo, D.-K. Kim, Y. Lee, Y.K. Chung, K.Y. Lim, J.S. Noh, J. Park and S.J. Son, Mortality Risk after Diagnosis of Early-Onset Alzheimer’s Disease versus Late-Onset Alzheimer’s Disease: A Propensity Score Matching Analysis (4) 1341–1348
Charidimou, A., see Valenti, R. (4) 1223–1227
Chen, C., see Shen, L. (1) 361–378
Chen, C.P., see Chong, J.R. (1) 157–166
Chen, J., L. Zhan, X. Lu, C. Xiao and N. Sun, The Alteration of ZiBuPiYin Recipe on Proteomic Profiling of Forebrain Postsynaptic Density of db/db Mice with Diabetes-Associated Cognitive Decline (2) 471–489
Chen, L., see Sokolow, S. (1) 229–237
Chen, Y., see Shen, L. (1) 361–378
Chételat, G., see Gaubert, M. (2) 717–731
Chidlow, G., J.P.M. Wood, J. Manavis, J. Finnie and R.J. Casson, Investigations into Retinal Pathology in the Early Stages of a Mouse Model of Alzheimer’s Disease (2) 655–675
Choi, S.H., see Chang, K.J. (4) 1341–1348
Chong, J.R., Y.L. Chai, J.H. Lee, D. Howlett, J. Attems, C.G. Ballard, D. Aarsland, P.T. Francis, C.P. Chen and M.K.P. Lai, Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer’s Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load (1) 157–166
Chung, Y.K., see Chang, K.J. (4) 1341–1348
Cieslak, A., see Ismail, Z. (3) 929–938
Claassen, J.A.H.R., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Clarimón, J., see Tell-Marti, G. (3) 1065–1074
Clodomiro, A., see Boccardi, V. (1) 239–248
Cohen-Bittan, J., see Zerah, L. (1) 145–156
Cohn-Hokke, P.E., see Louwersheimer, E. (1) 63–74
Colao, R., see Ferrari, R. (4) 1271–1278
Comi, G., ses Ferrari, L. (3) 1101–1107
Conforti, R., see Gareri, P. (2) 557–565
Conrod, P., see Khan, W. (3) 1159–1174
Cook, D.B., see Law, L.L. (1) 351–359
Coppedè, F., see Stoccoro, A. (4) 1451–1457
Cotroneo, A.M., see Gareri, P. (2) 557–565
Crespo-Biel, N., see Theunis, C. (2) 585–599
Crocco, E., see Loewenstein, D.A. (3) 1119–1126
Cross, N.E., see McKinnon, A.C. (4) 1373–1384
Croteau, E., see Castellano, C.-A. (4) 1459–1468
Cruchaga, C., see Haddick, P.C.G. (3) 1037–1054
Cui, D., see Xie, B. (1) 391–401
Cui, M.-Z., see Hu, C. (4) 1263–1269
Cummings, J., see Ismail, Z. (3) 929–938
Cunnane, S.C., see Castellano, C.-A. (4) 1459–1468
Cupidi, C., see Ferrari, R. (4) 1271–1278
Curiel, R.E., see Loewenstein, D.A. (3) 1119–1126
Curiel, R.E., see Matías-Guiu, J.A. (2) 733–742
Cutuli, D., see Gelfo, F. (4) 1505–1518
Czaja, S.J., see Loewenstein, D.A. (3) 1119–1126
D’Amelio, M., see Gelfo, F. (4) 1505–1518
Dai, S.-X., see Wang, Q. (4) 1525–1539
Dai, Z., see Wang, Z. (1) 415–428
Dalen, I., see Bergland, A.K. (2) 575–584
Darmal, B., see Amen, D.G. (1) 261–273
Dartigues, J.-F., see Pimouguet, C. (2) 509–517
Dashinimaev, E.B., A.S. Artyuhov, A.P. Bolshakov, E.A. Vorotelyak and A.V. Vasiliev, Neurons Derived from Induced Pluripotent Stem Cells of Patients with Down Syndrome Reproduce Early Stages of Alzheimer’s Disease Type Pathology in vitro (2) 835–847
Davidsdottir, S., see Valenti, R. (4) 1223–1227
Davis, T.M.E., see Peters, K.E. (3) 1127–1133
Davis, W.A., see Peters, K.E. (3) 1127–1133
De Bartolo, P., see Gelfo, F. (4) 1505–1518
de la Monte, S., see Lee, H.-K. (3) 1015–1036
de La Sayette, V., see Gaubert, M. (2) 717–731
de Oliveira, C.R., see van Waalwijk van Doorn, L.J.C. (2) 543–555
de Strooper, B., see Timmers, M. (4) 1437–1449
de Waepenaert, K., see Borghys, H. (2) 763–774
De Waepenaert, K., see Timmers, M. (4) 1437–1449
Desgranges, B., see Gaubert, M. (2) 717–731
Devijver, H., see Theunis, C. (2) 585–599
Dhar, A., see Sellal, F. (1) 37–46
Dhuyvetter, D., see Borghys, H. (2) 763–774
Di Giancamillo, A., see Buccarello, L. (4) 1279–1292
Di Iorio, G., see Benussi, L. (2) 825–833
Dionne, I.J., see Castellano, C.-A. (4) 1459–1468
DiPucchio, Z.Y., see Sellal, F. (1) 37–46
Domeneghini, C., see Buccarello, L. (4) 1279–1292
Dong, J., see Wu, L. (3) 893–898
Dong, Y., see Lu, Y. (4) 1469–1484
Doody, R.S., see Jia, J. (4) 1495–1504
Doran, E., D. Keator, E. Head, M.J. Phelan, R. Kim, M. Totoiu, J.R. Barrio, G.W. Small, S.G. Potkin and I.T. Lott, Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP (2) 459–470
Dougherty, R.J., see Law, L.L. (1) 351–359
Doumpoulakis, S., see Zygouris, S. (2) 619–627
Dowling, N.M., see Law, L.L. (1) 351–359
Duara, R., see Loewenstein, D.A. (3) 1119–1126
Duara, R., see N’Songo, A. (4) 1215–1222
Duffy, S.L., see McKinnon, A.C. (4) 1373–1384
Dykes, A.C., see Brooks, S.W. (1) 185–196
Dyś, A., see Zyśk, M. (3) 1145–1158
Ebel, D.L., C.G. Torkilsen and T.D. Ostrowski, Blunted Respiratory Responses in the Streptozotocin-Induced Alzheimer’s Disease Rat Model (3) 1197–1211
Edwards, D.F., see Law, L.L. (1) 351–359
Egret, S., see Gaubert, M. (2) 717–731
Einerson, J.A., see Law, L.L. (1) 351–359
Elger, B., see Ienca, M. (4) 1301–1340
Elman, J.A., see Granholm, E.L. (4) 1419–1428
Emek-Savaş, D.D., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Emon, M.A.E.K., A.T. Kodamullil, R. Karki, E. Younesi and M. Hofmann-Apitius, Using Drugs as Molecular Probes: A Computational Chemical Biology Approach in Neurodegenerative Diseases (2) 677–686
Endres, K., see Brandscheid, C. (2) 775–788
Engelborghs, S., see Timmers, M. (4) 1437–1449
Ercolani, S., see Boccardi, V. (1) 239–248
Eren, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Erkens, T., see Borghys, H. (2) 763–774
Ertekin-Taner, N., see N’Songo, A. (4) 1215–1222
Escott-Price, V., see Morgan, A.R. (1) 25–36
Estrella, M., see Apostolova, I. (1) 197–204
Eusebi, P., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Eustache, F., see Gaubert, M. (2) 717–731
Fabrice, J., see Ienca, M. (4) 1301–1340
Fang, H., see Fenesi, B. (1) 297–303
Farotti, L., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Farrer, L.A., see Haddick, P.C.G. (3) 1037–1054
Fasanaro, A.M., see Carotenuto, A. (2) 805–815
Fenesi, B., H. Fang, A. Kovacevic, M. Oremus, P. Raina and J.J. Heisz, Physical Exercise Moderates the Relationship of Apolipoprotein E (APOE) Genotype and Dementia Risk: A Population-Based Study (1) 297–303
Feng, N., see Li, L. (4) 1403–1417
Feng, R., see Li, L. (4) 1403–1417
Fenoglio, C., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Fernández-Castro, A., see Matías-Guiu, J.A. (2) 733–742
Fernández-Matarrubia, M., see Matías-Guiu, J.A. (2) 733–742
Fernández-Santiago, R., see Tell-Marti, G. (3) 1065–1074
Ferrari, L., S.-C. Huang, G. Magnani, A. Ambrosi, G. Comi and L. Leocani, Optical Coherence Tomography Reveals Retinal Neuroaxonal Thinning in Frontotemporal Dementia as in Alzheimer’s Disease (3) 1101–1107
Ferrari, R., M. Grassi, F. Graziano, F. Palluzzi, S. Archetti, E. Bonomi, A.C. Bruni, R.G. Maletta, L. Bernardi, C. Cupidi, R. Colao, I. Rainero, E. Rubino, L. Pinessi, D. Galimberti, E. Scarpini, M. Serpente, B. Nacmias, I. Piaceri, S. Bagnoli, G. Rossi, G. Giaccone, F. Tagliavini, L. Benussi, G. Binetti, R. Ghidoni, A. Singleton, J. Hardy, P. Momeni, A. Padovani and B. Borroni, Effects of Multiple Genetic Loci on Age at Onset in Frontotemporal Dementia (4) 1271–1278
Ferrer, I., see Boada, M. (1) 129–143
Ferri, R., see Stoccoro, A. (4) 1451–1457
Finnie, J., see Chidlow, G. (2) 655–675
Fischer, C.E., see Hird, M.A. (2) 447–452
Fischer, C.E., see Ismail, Z. (3) 929–938
Fitz, N.F., A.Y. Carter, V. Tapias, E.L. Castranio, R. Kodali, I. Lefterov and R. Koldamova, ABCA1 Deficiency Affects Basal Cognitive Deficits and Dendritic Density in Mice (3) 1075–1085
Flor, H., see Khan, W. (3) 1159–1174
Flory, M., see Baazaoui, N. (4) 1385–1401
Foiani, M.S., see Toombs, J. (3) 885–891
Forster, C.L., see Liu, P. (2) 743–761
Fortea, J., see Tell-Marti, G. (3) 1065–1074
Fortier, M., see Castellano, C.-A. (4) 1459–1468
Fotiadis, P., see Valenti, R. (4) 1223–1227
Fox, N.C., see Toombs, J. (3) 885–891
Francis, P.T., see Chong, J.R. (1) 157–166
Franz, C.E., see Granholm, E.L. (4) 1419–1428
Fratiglioni, L., see Khan, W. (3) 1159–1174
Frebourg, T., see Sellal, F. (1) 37–46
Freund-Levi, Y., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Frisoni, G.B., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Frommann, I., see Polcher, A. (3) 1185–1196
Frosch, M., see Sellal, F. (1) 37–46
Frouin, V., see Khan, W. (3) 1159–1174
Fujishima, M., A. Kawaguchi, N. Maikusa, R. Kuwano, T. Iwatsubo, H. Matsuda for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI), Sample Size Estimation for Alzheimer’s Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging (1) 75–88
Fülöp, T., see Castellano, C.-A. (4) 1459–1468
Gafner, V., see Theunis, C. (2) 585–599
Galimberti, D., see Ferrari, R. (4) 1271–1278
Galimberti, D., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Gallagher, C.L., see Law, L.L. (1) 351–359
Gallinat, J., see Khan, W. (3) 1159–1174
Gamez, M., see Loewenstein, D.A. (3) 1119–1126
Gapys, B., see Zyśk, M. (3) 1145–1158
Garavan, H., see Khan, W. (3) 1159–1174
García, E., see Gomez-Ramos, A. (3) 977–990
Garcimartín, A., see González-Muñoz, M.J. (3) 917–927
Gareri, P., A. Castagna, A.M. Cotroneo, D. Putignano, R. Conforti, F. Santamaria, S. Marino and S. Putignano, The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer’s Disease Study (2) 557–565
Garrido, P., see Gomez-Ramos, A. (3) 977–990
Gasse, C., see Nørgaard, A. (2) 707–716
Gaubert, M., N. Villain, B. Landeau, F. Mézenge, S. Egret, A. Perrotin, S. Belliard, V. de La Sayette, F. Eustache, B. Desgranges, G. Chételat and G. Rauchs, Neural Correlates of Self-Reference Effect in Early Alzheimer’s Disease (2) 717–731
Gauthier, S., see Ismail, Z. (3) 929–938
Geda, Y.E., see Ismail, Z. (3) 929–938
Gelfo, F., D. Cutuli, A. Nobili, P. De Bartolo, M. D’Amelio, L. Petrosini and C. Caltagirone, Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic Depletion: Effects on Memory Impairment and Neurodegeneration (4) 1505–1518
Genc, S., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Gertz, H.-J., see Sabbagh, M.N. (2) 441–446
Ghidoni, R., see Benussi, L. (2) 825–833
Ghidoni, R., see Ferrari, R. (4) 1271–1278
Giaccone, G., see Ferrari, R. (4) 1271–1278
Giakoumis, D., see Zygouris, S. (2) 619–627
Giampietro, V., see Khan, W. (3) 1159–1174
Gill, D.P., see Heath, M. (1) 167–183
Gillen, D.L., see Grill, J.D. (3) 939–946
Gimsing, L.N., see Thygesen, L.C. (4) 1429–1435
Gispert, J.D., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Glozman, T., J. Solomon, F. Pestilli and L. Guibas, for the Alzheimer’s Disease Neuroimaging Initiative, Shape-Attributes of Brain Structures as Biomarkers for Alzheimer’s Disease (1) 287–295
Goate, A.M., see Haddick, P.C.G. (3) 1037–1054
Goff, M.L., see Pimouguet, C. (2) 509–517
Gombert, C., see Sellal, F. (1) 37–46
Gomez-Ramos, A., A.J. Picher, E. García, P. Garrido, F. Hernandez, E. Soriano and J. Avila, Validation of Suspected Somatic Single Nucleotide Variations in the Brain of Alzheimer’s Disease Patients (3) 977–990
Gong, Y., see Li, L. (4) 1403–1417
González-Muñoz, M.J., A. Garcimartín, I. Meseguer, C.J. Mateos-Vega, J.M. Orellana, A. Peña-Fernández, J. Benedí and F.J. Sánchez-Muniz, Silicic Acid and Beer Consumption Reverses the Metal Imbalance and the Prooxidant Status Induced by Aluminum Nitrate in Mouse Brain (3) 917–927
Gower, A.C., see Wang, E. (1) 47–61
Gowland, P., see Khan, W. (3) 1159–1174
Graff, C., see Li, X. (1) 327–334
Graff-Radford, N., see N’Songo, A. (4) 1215–1222
Graham, R.R., see Haddick, P.C.G. (3) 1037–1054
Graham, S.J., see Hird, M.A. (2) 447–452
Granholm, E.L., M.S. Panizzon, J.A. Elman, A.J. Jak, R.L. Hauger, M.W. Bondi, M.J. Lyons, C.E. Franz and W.S. Kremen, Pupillary Responses as a Biomarker of Early Risk for Alzheimer’s Disease (4) 1419–1428
Grant, P., see Shukla, V. (1) 335–349
Grassi, M., see Ferrari, R. (4) 1271–1278
Graziano, F., see Ferrari, R. (4) 1271–1278
Greco, V., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Greenberg, S.M., see Sellal, F. (1) 37–46
Greenberg, S.M., see Valenti, R. (4) 1223–1227
Greig Custo, M.T., see N’Songo, A. (4) 1215–1222
Grifols, J.R., see Boada, M. (1) 129–143
Grignaschi, G., see Buccarello, L. (4) 1279–1292
Grill, J.D., A. Holbrook, A. Pierce, D. Hoang and D.L. Gillen, Attitudes toward Potential Participant Registries (3) 939–946
Grimm, M., see Brandscheid, C. (2) 775–788
Grunstein, R.R., see McKinnon, A.C. (4) 1373–1384
Guibas, L., see Glozman, T. (1) 287–295
Gul-Hinc, S., see Zyśk, M. (3) 1145–1158
Guo, Q., see Wang, Z. (1) 415–428
Guo, Y., see Shen, L. (1) 361–378
Guo, Y.-C., see Wang, Q. (4) 1525–1539
Gurol, M.E., see Valenti, R. (4) 1223–1227
Ha, A.Y., see Lee, H.-K. (3) 1015–1036
Haddick, P.C.G., J.L. Larson, N. Rathore, T.R. Bhangale, Q.T. Phung, K. Srinivasan, D.V. Hansen, J.R. Lill, Alzheimer’s Disease Genetic Consortium (ADGC), Alzheimer’s Disease Neuroimaging Initiative (ADNI), M.A. Pericak-Vance, J. Haines, L.A. Farrer, J.S. Kauwe, G.D. Schellenberg, C. Cruchaga, A.M. Goate, T.W. Behrens, R.J. Watts, R.R. Graham, J.S. Kaminker and M. van der Brug, A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer’s Disease Brains (3) 1037–1054
Haines, J., see Haddick, P.C.G. (3) 1037–1054
Hall, A., see Suhonen, N.-M. (4) 1241–1251
Hallikainen, I., see Suhonen, N.-M. (4) 1241–1251
Ham, L.S., see Meijboom, R. (2) 789–804
Hampel, H., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Han, F.-F., see Wang, Q. (4) 1525–1539
Hannequin, D., see Sellal, F. (1) 37–46
Hänninen, T., see Suhonen, N.-M. (4) 1241–1251
Hansen, D.V., see Haddick, P.C.G. (3) 1037–1054
Hansen, E.S., see Nørgaard, A. (2) 707–716
Hao, K., see Ho, L. (1) 305–315
Hardy, J., see Ferrari, R. (4) 1271–1278
Hariramani, R., see Matías-Guiu, J.A. (2) 733–742
Hartikainen, S., see Koponen, M. (1) 107–118
Hartikainen, S., see Lampela, P. (1) 119–128
Hartmann, T., see Brandscheid, C. (2) 775–788
Hashimoto, Y., see Kamikubo, Y. (2) 641–653
Hattori, N., see Jurjević, I. (1) 317–325
Hauger, R.L., see Granholm, E.L. (4) 1419–1428
He, Y., see Wang, Z. (1) 415–428
Head, E., see Doran, E. (2) 459–470
Heath, M., E. Shellington, S. Titheridge, D.P. Gill and R.J. Petrella, A 24-Week Multi-Modality Exercise Program Improves Executive Control in Older Adults with a Self-Reported Cognitive Complaint: Evidence from the Antisaccade Task (1) 167–183
Heinz, A., see Khan, W. (3) 1159–1174
Heisz, J.J., see Fenesi, B. (1) 297–303
Helmer, C., see Pimouguet, C. (2) 509–517
Hemmy, L.S., see Liu, P. (2) 743–761
Hermann, B.P., see Law, L.L. (1) 351–359
Hernandez, F., see Gomez-Ramos, A. (3) 977–990
Hernández, I., see Boada, M. (1) 129–143
Herrmann, N., see Ismail, Z. (3) 929–938
Herukka, S.-K., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Heslegrave, A., see Toombs, J. (3) 885–891
Hickie, I.B., see McKinnon, A.C. (4) 1373–1384
Hickman, D.T., see Theunis, C. (2) 585–599
Hietanen, M., see Kallio, E.-L. (4) 1349–1372
Hird, M.A., K.A. Vesely, C.E. Fischer, S.J. Graham, G. Naglie and T.A. Schweizer, Investigating Simulated Driving Errors in Amnestic Single- and Multiple-Domain Mild Cognitive Impairment (2) 447–452
Hisatsune, T., see Matsuda, T. (1) 1–23
Ho, L., M. Legere, T. Li, S. Levine, K. Hao, B. Valcarcel and G.M. Pasinetti, Autonomic Nervous System Dysfunctions as a Basis for a Predictive Model of Risk of Neurological Disorders in Subjects with Prior History of Traumatic Brain Injury: Implications in Alzheimer’s Disease (1) 305–315
Hoang, D., see Grill, J.D. (3) 939–946
Hodges, J.R., see Kaizik, C. (3) 1109–1117
Hofmann-Apitius, M., see Emon, M.A.E.K. (2) 677–686
Holbrook, A., see Grill, J.D. (3) 939–946
Holstege, H., see Louwersheimer, E. (1) 63–74
Hong, C.H., see Chang, K.J. (4) 1341–1348
Hong, X., see Wang, H. (3) 875–883
Horváth, A., A. Szűcs, G. Barcs and A. Kamondi, Sleep EEG Detects Epileptiform Activity in Alzheimer’s Disease with High Sensitivity (3) 1175–1183
Howlett, D., see Chong, J.R. (1) 157–166
Hsieh-Li, H.-M., see Lin, T.-S. (3) 959–976
Hu, C., J. Xu, L. Zeng, T. Li, M.-Z. Cui and X. Xu, Pen-2 and Presenilin are Sufficient to Catalyze Notch Processing (4) 1263–1269
Huang, E.S., see Liu, P. (2) 743–761
Huang, J.-F., see Wang, Q. (4) 1525–1539
Huang, R.-S., see Lin, T.-S. (3) 959–976
Huang, S.-C., ses Ferrari, L. (3) 1101–1107
Hulsman, M., see Louwersheimer, E. (1) 63–74
Hvidt, N.C., see Thygesen, L.C. (4) 1429–1435
Ienca, M., J. Fabrice, B. Elger, M. Caon, A.S. Pappagallo, R.W. Kressig and T. Wangmo, Intelligent Assistive Technology for Alzheimer’s Disease and Other Dementias: A Systematic Review (4) 1301–1340
Igel, H.J., see Apostolova, I. (1) 197–204
Ihara, M., see Kuriyama, N. (4) 1253–1262
Ikram, U., see Agyemang, C. (1) 205–213
Imbeault, H., see Castellano, C.-A. (4) 1459–1468
Imtiaz, B., A.M. Tolppanen, A. Solomon, H. Soininen and M. Kivipelto, Estradiol and Cognition in the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) Cohort Study (2) 453–458
Innes, K.E., T.K. Selfe, D.S. Khalsa and S. Kandati, Meditation and Music Improve Memory and Cognitive Function in Adults with Subjective Cognitive Decline: A Pilot Randomized Controlled Trial (3) 899–916
Iqbal, K., see Baazaoui, N. (4) 1385–1401
Ismail, Z., L. Agüera-Ortiz, H. Brodaty, A. Cieslak, J. Cummings, C.E. Fischer, S. Gauthier, Y.E. Geda, N. Herrmann, J. Kanji, K.L. Lanctôt, D.S. Miller, M.E. Mortby, C.U. Onyike, P.B. Rosenberg, E.E. Smith, G.S. Smith, D.L. Sultzer and C. Lyketsos for the NPS Professional Interest Area of the International Society of to Advance Alzheimer’s Research and Treatment (NPS-PIA of ISTAART), The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations (3) 929–938
Itamura, K., see Lee, H.-K. (3) 1015–1036
Ittermann, B., see Khan, W. (3) 1159–1174
Iwata, N., see Matsunaga, S. (4) 1229–1239
Iwatsubo, T., see Fujishima, M. (1) 75–88
Jacob, L., J. Bohlken and K. Kostev, Prevalence of Use of Cardiovascular Drugs in Dementia Patients Treated in General Practices in Germany (4) 1519–1524
Jacob, L., J. Bohlken and K. Kostev, Risk Factors for Mild Cognitive Impairment in German Primary Care Practices (1) 379–384
Jacobs, T., see Borghys, H. (2) 763–774
Jak, A.J., see Granholm, E.L. (4) 1419–1428
James, B.D., see Yarchoan, M. (2) 699–706
Jaul, E. and O. Meiron, Dementia and Pressure Ulcers: Is There a Close Pathophysiological Interrelation? (3) 861–866
Jensen-Dahm, C., see Nørgaard, A. (2) 707–716
Jessen, F., see Polcher, A. (3) 1185–1196
Ji, H.-F., see Shen, L. (1) 385–390
Jia, J., C. Wei, L. Jia, Y. Tang, J. Liang, A. Zhou, F. Li, L. Shi and R.S. Doody, Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer’s Disease: A Randomized Controlled Trial (4) 1495–1504
Jia, J., see Wu, L. (3) 893–898
Jia, L., see Jia, J. (4) 1495–1504
Jiang, L., see Xie, B. (1) 391–401
Jiang, Y., see Tan, L. (2) 629–640
Johansen, C., see Thygesen, L.C. (4) 1429–1435
Johnson, S.C., see Law, L.L. (1) 351–359
Jokelainen, J., see Suhonen, N.-M. (4) 1241–1251
Jones, L., see Morgan, A.R. (1) 25–36
Jongbloed, W., see Slot, R.E.R. (2) 687–697
Jorandby, L., see Amen, D.G. (1) 261–273
Jovalekic, A., see Sabbagh, M.N. (2) 441–446
Jurjević, I., M. Miyajima, I. Ogino, C. Akiba, M. Nakajima, A. Kondo, M. Kikkawa, M. Kanai, N. Hattori and H. Arai, Decreased Expression of hsa-miR-4274 in Cerebrospinal Fluid of Normal Pressure Hydrocephalus Mimics with Parkinsonian Syndromes (1) 317–325
Kaddoumi, A., see Mohamed, L.A. (3) 1087–1099
Kaizik, C., J. Caga, J. Camino, C.M. O’Connor, C. McKinnon, J.R. Oyebode, O. Piguet, J.R. Hodges and E. Mioshi, Factors Underpinning Caregiver Burden in Frontotemporal Dementia Differ in Spouses and their Children (3) 1109–1117
Kallio, E.-L., H. Öhman, H. Kautiainen, M. Hietanen and K. Pitkälä, Cognitive Training Interventions for Patients with Alzheimer’s Disease: A Systematic Review (4) 1349–1372
Kalpouzos, G., see Khan, W. (3) 1159–1174
Kamikubo, Y., N. Takasugi, K. Niisato, Y. Hashimoto and T. Sakurai, Consecutive Analysis of BACE1 Function on Developing and Developed Neuronal Cells (2) 641–653
Kaminker, J.S., see Haddick, P.C.G. (3) 1037–1054
Kamondi, A., see Horváth, A. (3) 1175–1183
Kanai, M., see Jurjević, I. (1) 317–325
Kandati, S., see Innes, K.E. (3) 899–916
Kang, D.R., see Chang, K.J. (4) 1341–1348
Kanji, J., see Ismail, Z. (3) 929–938
Karagiannidis, C., see Zygouris, S. (2) 619–627
Karki, R., see Emon, M.A.E.K. (2) 677–686
Kautiainen, H., see Kallio, E.-L. (4) 1349–1372
Kauwe, J.S., see Haddick, P.C.G. (3) 1037–1054
Kawaguchi, A., see Fujishima, M. (1) 75–88
Keator, D., see Doran, E. (2) 459–470
Kesavapany, S., see Shukla, V. (1) 335–349
Kester, M.I., see Slot, R.E.R. (2) 687–697
Khalsa, D.S., see Innes, K.E. (3) 899–916
Khan, W., V. Giampietro, T. Banaschewski, G.J. Barker, A.L.W. Bokde, C. Büchel, P. Conrod, H. Flor, V. Frouin, H. Garavan, P. Gowland, A. Heinz, B. Ittermann, H. Lemaître, F. Nees, T. Paus, Z. Pausova, M. Rietschel, M.N. Smolka, A. Ströhle, J. Gallinat, B. Vellas, H. Soininen, I. Kloszewska, M. Tsolaki, P. Mecocci, C. Spenger, V.L. Villemagne, C.L. Masters, J.-S. Muehlboeck, L. Bäckman, L. Fratiglioni, G. Kalpouzos, L.-O. Wahlund, G. Schumann, S. Lovestone, S.C.R. Williams, E. Westman, A. Simmons, Alzheimer’s Disease Neuroimaging Initiative, AddNeuroMed Consortium, Australian, Imaging, Biomarkers, and Lifestyle Study Research Group and and the IMAGEN consortium, A Multi-Cohort Study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer’s Disease (3) 1159–1174
Khiami, F., see Zerah, L. (1) 145–156
Kikkawa, M., see Jurjević, I. (1) 317–325
Kim, B., see Kim, Y.J. (3) 1007–1014
Kim, D.-K., see Chang, K.J. (4) 1341–1348
Kim, K.W., see Kim, Y.J. (3) 1007–1014
Kim, R., see Doran, E. (2) 459–470
Kim, S.Y., see Chang, K.J. (4) 1341–1348
Kim, Y.J., H. An, B. Kim, Y.S. Park and K.W. Kim, An International Comparative Study on Driving Regulations on People with Dementia (3) 1007–1014
Kishi, T., see Matsunaga, S. (4) 1229–1239
Kivipelto, M., see Imtiaz, B. (2) 453–458
Kliper, E., see Molad, J. (4) 1293–1299
Kloszewska, I., see Khan, W. (3) 1159–1174
Kodali, R., see Fitz, N.F. (3) 1075–1085
Kodamullil, A.T., see Emon, M.A.E.K. (2) 677–686
Koek, H.L., see Agyemang, C. (1) 205–213
Koene, T., see Louwersheimer, E. (1) 63–74
Koene, T., see Van Mierlo, L.D. (1) 249–259
Koldamova, R., see Fitz, N.F. (3) 1075–1085
Kondo, A., see Jurjević, I. (1) 317–325
Kondo, M., see Kuriyama, N. (4) 1253–1262
Koponen, M., H. Taipale, P. Lavikainen, A. Tanskanen, J. Tiihonen, A.-M. Tolppanen, R. Ahonen and S. Hartikainen, Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer’s Disease (1) 107–118
Koppara, A., see Polcher, A. (3) 1185–1196
Korcarz, C.E., see Law, L.L. (1) 351–359
Korczyn, A.D., see Molad, J. (4) 1293–1299
Koscik, R.L., see Law, L.L. (1) 351–359
Kostev, K., see Jacob, L. (1) 379–384
Kostev, K., see Jacob, L. (4) 1519–1524
Kotani, R., Y. Urano, H. Sugimoto and N. Noguchi, Decrease of Amyloid-β Levels by Curcumin Derivative via Modulation of Amyloid-β Protein Precursor Trafficking (2) 529–542
Kourkoulis, C.E., see Sellal, F. (1) 37–46
Kovacevic, A., see Fenesi, B. (1) 297–303
Kowall, N., see Wang, E. (1) 47–61
Koyama, T., see Kuriyama, N. (4) 1253–1262
Kremen, W.S., see Granholm, E.L. (4) 1419–1428
Kressig, R.W., see Ienca, M. (4) 1301–1340
Krüger, J., see Suhonen, N.-M. (4) 1241–1251
Kuijf, H.J., see Valenti, R. (4) 1223–1227
Kuiperij, H.B., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Kuntz, S., see Shukla, V. (1) 335–349
Kunz, L., M. Reuter, N. Axmacher and C. Montag, Conscientiousness is Negatively Associated with Grey Matter Volume in Young APOE ɛ4-Carriers (3) 1135–1144
Kuriyama, N., M. Ihara, T. Mizuno, E. Ozaki, D. Matsui, I. Watanabe, T. Koyama, M. Kondo, T. Tokuda, A. Tamura, K. Yamada, K. Akazawa, K. Takeda, A. Takada, S. Mizuno, M. Nakagawa and Y. Watanabe, Association between Mid-Regional Proadrenomedullin Levels and Progression of Deep White Matter Lesions in the Brain Accompanying Cognitive Decline (4) 1253–1262
Kuskowski, M.A., see Liu, P. (2) 743–761
Kuwano, R., see Fujishima, M. (1) 75–88
Kwon, B., see Lee, H.-K. (3) 1015–1036
Lacombe, G., see Castellano, C.-A. (4) 1459–1468
Lafuente, A., see Boada, M. (1) 129–143
Lagopoulos, J., see McKinnon, A.C. (4) 1373–1384
Lai, M.K.P., see Chong, J.R. (1) 157–166
Lämmler, G., see Apostolova, I. (1) 197–204
Lampela, P., A.-M. Tolppanen, A. Tanskanen, J. Tiihonen, S. Hartikainen and H. Taipale, Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer’s Disease: A Nested Case-Control Study (1) 119–128
Lanctôt, K.L., see Ismail, Z. (3) 929–938
Landau, S., see Sundermann, E.E. (3) 947–957
Landeau, B., see Gaubert, M. (2) 717–731
Lange, C., see Apostolova, I. (1) 197–204
Langlois, F., see Castellano, C.-A. (4) 1459–1468
Larsen, A.I., see Bergland, A.K. (2) 575–584
Larson, J.L., see Haddick, P.C.G. (3) 1037–1054
Last, N., E. Tufts and L.E. Auger, The Effects of Meditation on Grey Matter Atrophy and Neurodegeneration: A Systematic Review (1) 275–286
Lattanzio, F., see Persson, T. (2) 601–617
Lavikainen, P., see Koponen, M. (1) 107–118
Law, L.L., S.A. Schultz, E.A. Boots, J.A. Einerson, R.J. Dougherty, J.M. Oh, C.E. Korcarz, D.F. Edwards, R.L. Koscik, N.M. Dowling, C.L. Gallagher, B.B. Bendlin, C.M. Carlsson, S. Asthana, B.P. Hermann, M.A. Sager, S.C. Johnson, D.B. Cook, J.H. Stein and O.C. Okonkwo, Chronotropic Response and Cognitive Function in a Cohort at Risk for Alzheimer’s Disease (1) 351–359
Lee, C.-H., see Lin, T.-S. (3) 959–976
Lee, H.-K., B. Kwon, C.A. Lemere, S. de la Monte, K. Itamura, A.Y. Ha and H.W. Querfurth, mTORC2 (Rictor) in Alzheimer’s Disease and Reversal of Amyloid-β Expression-Induced Insulin Resistance and Toxicity in Rat Primary Cortical Neurons (3) 1015–1036
Lee, J.D., see Chang, K.J. (4) 1341–1348
Lee, J.H., see Chong, J.R. (1) 157–166
Lee, K.S., see Chang, K.J. (4) 1341–1348
Lee, Y., see Chang, K.J. (4) 1341–1348
Lefterov, I., see Fitz, N.F. (3) 1075–1085
Legere, M., see Ho, L. (1) 305–315
Lei, P., see Betrie, A.H. (2) 849–860
Lemaître, H., see Khan, W. (3) 1159–1174
Lemere, C.A., see Lee, H.-K. (3) 1015–1036
Leocani, L., ses Ferrari, L. (3) 1101–1107
Lethias, C., see Salza, R. (3) 991–1005
Levine, S., see Ho, L. (1) 305–315
Lewis, S.J.G., see McKinnon, A.C. (4) 1373–1384
Li, F., see Jia, J. (4) 1495–1504
Li, G.-H., see Wang, Q. (4) 1525–1539
Li, H., see Tan, L. (2) 629–640
Li, J., see Li, L. (4) 1403–1417
Li, J., see Wu, L. (3) 893–898
Li, L., S. Xu, L. Liu, R. Feng, Y. Gong, X. Zhao, J. Li, J. Cai, N. Feng, L. Wang, X. Wang and Y. Peng, Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25–35-induced Rat Model of Alzheimer’s Disease (4) 1403–1417
Li, S., see Shen, L. (1) 361–378
Li, T., see Ho, L. (1) 305–315
Li, T., see Hu, C. (4) 1263–1269
Li, W.-X., see Wang, Q. (4) 1525–1539
Li, X., E. Westman, S. Thordardottir, A.K. Ståhlbom, O. Almkvist, K. Blennow, L.-O. Wahlund and C. Graff, The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer’s Disease (1) 327–334
Li, X., see Sokolow, S. (1) 229–237
Liang, J., see Jia, J. (4) 1495–1504
Liang, M.-C., see Lin, T.-S. (3) 959–976
Liao, L., see Shen, L. (1) 361–378
Liese, S., see Apostolova, I. (1) 197–204
Lill, J.R., see Haddick, P.C.G. (3) 1037–1054
Lim, K.Y., see Chang, K.J. (4) 1341–1348
Lin, T.-S., H.-J. Tsai, C.-H. Lee, Y.-Q. Song, R.-S. Huang, H.-M. Hsieh-Li, M.-C. Liang and Y. Lin, An Improved Drugs Screening System Reveals that Baicalein Ameliorates the Aβ/AMPA/NMDA-Induced Depolarization of Neurons (3) 959–976
Lin, Y., see Lin, T.-S. (3) 959–976
Lipton, R.B., see Sundermann, E.E. (3) 947–957
Liu, D., see Wang, Z. (1) 415–428
Liu, J., see Wu, L. (3) 893–898
Liu, L., see Li, L. (4) 1403–1417
Liu, L., see Shen, L. (1) 385–390
Liu, P., J.H. Reichl, E.R. Rao, B.M. McNellis, E.S. Huang, L.S. Hemmy, C.L. Forster, M.A. Kuskowski, D.R. Borchelt, R. Vassar, K.H. Ashe and K.R. Zahs, Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid-β Protein Precursor Transgenic Mice (2) 743–761
Liu, Q., see Shen, L. (1) 361–378
Liu, W., see Tan, L. (2) 629–640
Liu, W., see Xie, B. (1) 391–401
Liu, Y., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Liu, Z., see Xie, B. (1) 391–401
Lladó, A., see Tell-Marti, G. (3) 1065–1074
Lladó, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Lleó, A., see Tell-Marti, G. (3) 1065–1074
Lleó, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Loewenstein, D.A., R.E. Curiel, C. Wright, X. Sun, N. Alperin, E. Crocco, S.J. Czaja, A. Raffo, A. Penate, J. Melo, K. Capp, M. Gamez and R. Duara, Recovery from Proactive Semantic Interference in Mild Cognitive Impairment and Normal Aging: Relationship to Atrophy in Brain Regions Vulnerable to Alzheimer’s Disease (3) 1119–1126
Loewenstein, D.A., see Matías-Guiu, J.A. (2) 733–742
Longo, A., see Boccardi, V. (1) 239–248
Lopez, O.L., see Boada, M. (1) 129–143
Lott, I.T., see Doran, E. (2) 459–470
Louwersheimer, E., P.E. Cohn-Hokke, Y.A.L. Pijnenburg, M.M. Weiss, E.A. Sistermans, A.J. Rozemuller, M. Hulsman, J.C. van Swieten, C.M. van Duijn, F. Barkhof, T. Koene, P. Scheltens, W.M. Van der Flier and H. Holstege, Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity (1) 63–74
Lovestone, S., see Khan, W. (3) 1159–1174
Lu, X., see Chen, J. (2) 471–489
Lu, Y., Y. Dong, D. Tucker, R. Wang, M.E. Ahmed, D. Brann and Q. Zhang, Treadmill Exercise Exerts Neuroprotection and Regulates Microglial Polarization and Oxidative Stress in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer’s Disease (4) 1469–1484
Lunn, M.P., see Toombs, J. (3) 885–891
Lyketsos, C., see Ismail, Z. (3) 929–938
Lyons, M.J., see Granholm, E.L. (4) 1419–1428
Magnani, G., ses Ferrari, L. (3) 1101–1107
Maikusa, N., see Fujishima, M. (1) 75–88
Maioli, S., see Persson, T. (2) 601–617
Majounie, E., see Morgan, A.R. (1) 25–36
Maki, P.M., see Sundermann, E.E. (3) 947–957
Maletta, R.G., see Ferrari, R. (4) 1271–1278
Manavis, J., see Chidlow, G. (2) 655–675
Manzo, V., see Carotenuto, A. (2) 805–815
Marelli, C., see Sellal, F. (1) 37–46
Marino, S., see Gareri, P. (2) 557–565
Marmarelis, V.Z., D.C. Shin, T. Tarumi and R. Zhang, Comparison of Model-Based Indices of Cerebral Autoregulation and Vasomotor Reactivity Using Transcranial Doppler versus Near-Infrared Spectroscopy in Patients with Amnestic Mild Cognitive Impairment (1) 89–105
Martinez-Almoyna, L., see Sellal, F. (1) 37–46
Martins, R.N., see Peters, K.E. (3) 1127–1133
Masters, C.L., see Khan, W. (3) 1159–1174
Masters, C.L., see Peters, K.E. (3) 1127–1133
Masters, C.L., see Sabbagh, M.N. (2) 441–446
Mateos-Vega, C.J., see González-Muñoz, M.J. (3) 917–927
Matías-Guiu, J., see Matías-Guiu, J.A. (2) 733–742
Matías-Guiu, J.A., R.E. Curiel, T. Rognoni, M. Valles-Salgado, M. Fernández-Matarrubia, R. Hariramani, A. Fernández-Castro, T. Moreno-Ramos, D.A. Loewenstein and J. Matías-Guiu, Validation of the Spanish Version of the LASSI-L for Diagnosing Mild Cognitive Impairment and Alzheimer’s Disease (2) 733–742
Matsuda, H., see Fujishima, M. (1) 75–88
Matsuda, T. and T. Hisatsune, Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of AβPPswe/PSEN1dE9 Alzheimer’s Disease Model Mice Fed a High-Fat Diet (1) 1–23
Matsui, D., see Kuriyama, N. (4) 1253–1262
Matsunaga, S., T. Kishi and N. Iwata, Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson’s Disease: A Meta-Analysis (4) 1229–1239
Matte, J.J., see Castellano, C.-A. (4) 1459–1468
Mäurer, A., see Apostolova, I. (1) 197–204
McKinnon, A.C., S.L. Duffy, N.E. Cross, Z. Terpening, R.R. Grunstein, J. Lagopoulos, J. Batchelor, I.B. Hickie, S.J.G. Lewis, J.M. Shine and S.L. Naismith, Functional Connectivity in the Default Mode Network is Reduced in Association with Nocturnal Awakening in Mild Cognitive Impairment (4) 1373–1384
McKinnon, C., see Kaizik, C. (3) 1109–1117
McLimans, K.E., A.A. Willette and for the Alzheimer’s Disease Neuroimaging Initiative, Autotaxin is Related to Metabolic Dysfunction and Predicts Alzheimer’s Disease Outcomes (1) 403–413
McNellis, B.M., see Liu, P. (2) 743–761
Mecocci, P., see Boccardi, V. (1) 239–248
Mecocci, P., see Khan, W. (3) 1159–1174
Meijboom, R., R.M.E. Steketee, L.S. Ham, A. van der Lugt, J.C. van Swieten and M. Smits, Differential Hemispheric Predilection of Microstructural White Matter and Functional Connectivity Abnormalities between Respectively Semantic and Behavioral Variant Frontotemporal Dementia (2) 789–804
Meiron, O., see Jaul, E. (3) 861–866
Melcangi, R.C., see Buccarello, L. (4) 1279–1292
Melo, J., see Loewenstein, D.A. (3) 1119–1126
Mendez, A.J., see Squitti, R. (3) 1055–1064
Mercken, M., see Timmers, M. (4) 1437–1449
Meseguer, I., see González-Muñoz, M.J. (3) 917–927
Meulenbroek, O., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Meysami, S., see Amen, D.G. (1) 261–273
Mézenge, F., see Gaubert, M. (2) 717–731
Meziere, A., see Zerah, L. (1) 145–156
Migliore, L., see Stoccoro, A. (4) 1451–1457
Miller, D.S., see Ismail, Z. (3) 929–938
Miné, M., see Sellal, F. (1) 37–46
Mioshi, E., see Kaizik, C. (3) 1109–1117
Mishra, S.K., see Shukla, V. (1) 335–349
Miyajima, M., see Jurjević, I. (1) 317–325
Mizuno, S., see Kuriyama, N. (4) 1253–1262
Mizuno, T., see Kuriyama, N. (4) 1253–1262
Moechars, D., see Timmers, M. (4) 1437–1449
Mohamed, L.A., H. Zhu, Y.M. Mousa, E. Wang, W.Q. Qiu and A. Kaddoumi, Amylin Enhances Amyloid-β Peptide Brain to Blood Efflux Across the Blood-Brain Barrier (3) 1087–1099
Molad, J., E. Kliper, A.D. Korczyn, E. Ben Assayag, D. Ben Bashat, S. Shenhar-Tsarfaty, O. Aizenstein, L. Shopin, N.M. Bornstein and E. Auriel, Only White Matter Hyperintensities Predicts Post-Stroke Cognitive Performances Among Cerebral Small Vessel Disease Markers: Results from the TABASCO Study (4) 1293–1299
Molinuevo, J.L., see Tell-Marti, G. (3) 1065–1074
Molinuevo, J.L., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Momeni, P., see Ferrari, R. (4) 1271–1278
Monacelli, F., A. Signori, L. Roffredo, K. Pace, A. Nencioni, G. Pickering, M. Nicolas and P. Odetti, Algoplus® Scale in Older Patients with Dementia: A Reliable Real-World Pain Assessment Tool (2) 519–527
Montag, C., see Kunz, L. (3) 1135–1144
Moreno-Ramos, T., see Matías-Guiu, J.A. (2) 733–742
Morgan, A.R., S. Touchard, C. O’Hagan, R. Sims, E. Majounie, V. Escott-Price, L. Jones, J. Williams and B.P. Morgan, The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer’s Disease (1) 25–36
Morgan, B.P., see Morgan, A.R. (1) 25–36
Mortby, M.E., see Ismail, Z. (3) 929–938
Mousa, Y.M., see Mohamed, L.A. (3) 1087–1099
Muehlboeck, J.-S., see Khan, W. (3) 1159–1174
Muhs, A., see Theunis, C. (2) 585–599
Muñoz, J., see Boada, M. (1) 129–143
Murata, S., see Sugimoto, T. (2) 567–574
Murayama, S., see Sabbagh, M.N. (2) 441–446
N’Songo, A., M.M. Carrasquillo, X. Wang, T. Nguyen, Y. Asmann, S.G. Younkin, M. Allen, R. Duara, M.T. Greig Custo, N. Graff-Radford and N. Ertekin-Taner, Comprehensive Screening for Disease Risk Variants in Early-Onset Alzheimer’s Disease Genes in African Americans Identifies Novel PSEN Variants (4) 1215–1222
Na, D.L., see Chang, K.J. (4) 1341–1348
Nacmias, B., see Ferrari, R. (4) 1271–1278
Nacmias, B., see Stoccoro, A. (4) 1451–1457
Naglie, G., see Hird, M.A. (2) 447–452
Naismith, S.L., see McKinnon, A.C. (4) 1373–1384
Nakagawa, M., see Kuriyama, N. (4) 1253–1262
Nakajima, M., see Jurjević, I. (1) 317–325
Nakanishi, M., J. Niimura, S. Yamasaki and A. Nishida, Death of Dementia Patients in Psychiatric Hospitals and Regional Supply of Psychiatric Services: Study of the National Data from 1996 to 2014 in Japan (2) 817–824
Nees, F., see Khan, W. (3) 1159–1174
Nencioni, A., see Monacelli, F. (2) 519–527
Neri, C., see Zerah, L. (1) 145–156
Nguyen, T., see N’Songo, A. (4) 1215–1222
Ni, J., see Shen, L. (1) 361–378
Nicolas, G., see Sellal, F. (1) 37–46
Nicolas, M., see Monacelli, F. (2) 519–527
Niida, S., see Sugimoto, T. (2) 567–574
Niimura, J., see Nakanishi, M. (2) 817–824
Niisato, K., see Kamikubo, Y. (2) 641–653
Nishida, A., see Nakanishi, M. (2) 817–824
Nobili, A., see Gelfo, F. (4) 1505–1518
Nobili, F.M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Noguchi, N., see Kotani, R. (2) 529–542
Noh, J.S., see Chang, K.J. (4) 1341–1348
Nørgaard, A., C. Jensen-Dahm, C. Gasse, E.S. Hansen and G. Waldemar, Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors (2) 707–716
Norredam, M., see Agyemang, C. (1) 205–213
Ntovas, K., see Zygouris, S. (2) 619–627
Núñez, L., see Boada, M. (1) 129–143
O’Connor, C.M., see Kaizik, C. (3) 1109–1117
O’Hagan, C., see Morgan, A.R. (1) 25–36
Obisesan, T.O., see Boada, M. (1) 129–143
Odetti, P., see Monacelli, F. (2) 519–527
Oesterlé, H., see Sellal, F. (1) 37–46
Ogino, I., see Jurjević, I. (1) 317–325
Oguz, K.K., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Oh, J.M., see Law, L.L. (1) 351–359
Öhman, H., see Kallio, E.-L. (4) 1349–1372
Okonkwo, O.C., see Law, L.L. (1) 351–359
Olazarán, J., see Boada, M. (1) 129–143
Ono, R., see Sugimoto, T. (2) 567–574
Onyike, C.U., see Ismail, Z. (3) 929–938
Orellana, J.M., see González-Muñoz, M.J. (3) 917–927
Oremus, M., see Fenesi, B. (1) 297–303
Ormaechea, J.F., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Ortiz, P., see Boada, M. (1) 129–143
Ostrowski, T.D., see Ebel, D.L. (3) 1197–1211
Oyebode, J.R., see Kaizik, C. (3) 1109–1117
Ozaki, E., see Kuriyama, N. (4) 1253–1262
Pace, K., see Monacelli, F. (2) 519–527
Padovani, A., see Ferrari, R. (4) 1271–1278
Páez, A., see Boada, M. (1) 129–143
Palluzzi, F., see Ferrari, R. (4) 1271–1278
Pang, W., see Tan, L. (2) 629–640
Panizzon, M.S., see Granholm, E.L. (4) 1419–1428
Pant, H.C., see Shukla, V. (1) 335–349
Pantoni, L., see Valenti, R. (4) 1223–1227
Pappagallo, A.S., see Ienca, M. (4) 1301–1340
Paquet, N., see Castellano, C.-A. (4) 1459–1468
Park, J., see Chang, K.J. (4) 1341–1348
Park, Y.S., see Kim, Y.J. (3) 1007–1014
Parnetti, L., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Pasinetti, G.M., see Ho, L. (1) 305–315
Paterson, R.W., see Toombs, J. (3) 885–891
Paus, T., see Khan, W. (3) 1159–1174
Pausova, Z., see Khan, W. (3) 1159–1174
Peña-Fernández, A., see González-Muñoz, M.J. (3) 917–927
Penate, A., see Loewenstein, D.A. (3) 1119–1126
Peng, Y., see Li, L. (4) 1403–1417
Pereira, J., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Pericak-Vance, M.A., see Haddick, P.C.G. (3) 1037–1054
Perrotin, A., see Gaubert, M. (2) 717–731
Persson, T., F. Lattanzio, J. Calvo-Garrido, R. Rimondini, M. Rubio-Rodrigo, E. Sundström, S. Maioli, A. Sandebring-Matton and Á. Cedazo-Mínguez, Apolipoprotein E4 Elicits Lysosomal Cathepsin D Release, Decreased Thioredoxin-1 Levels, and Apoptosis (2) 601–617
Pestilli, F., see Glozman, T. (1) 287–295
Peters, K.E., W.A. Davis, K. Taddei, R.N. Martins, C.L. Masters, T.M.E. Davis and D.G. Bruce, Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study (3) 1127–1133
Peters, O., see Sabbagh, M.N. (2) 441–446
Peters, R., see Anstey, K.J. (1) 215–228
Petrella, R.J., see Heath, M. (1) 167–183
Petrosini, L., see Gelfo, F. (4) 1505–1518
Pfeifer, A., see Theunis, C. (2) 585–599
Phelan, M.J., see Doran, E. (2) 459–470
Phung, Q.T., see Haddick, P.C.G. (3) 1037–1054
Piaceri, I., see Ferrari, R. (4) 1271–1278
Piaz, F.D., see Benussi, L. (2) 825–833
Picco, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Picher, A.J., see Gomez-Ramos, A. (3) 977–990
Pickering, G., see Monacelli, F. (2) 519–527
Pierce, A., see Grill, J.D. (3) 939–946
Pietrzik, C.U., see Brandscheid, C. (2) 775–788
Piguet, O., see Kaizik, C. (3) 1109–1117
Pihlgren, M., see Theunis, C. (2) 585–599
Pijnenburg, Y.A.L., see Louwersheimer, E. (1) 63–74
Pikkarainen, M., see Suhonen, N.-M. (4) 1241–1251
Pikkarainen, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Pimouguet, C., M.L. Goff, J. Wittwer, J.-F. Dartigues and C. Helmer, Benefits of Occupational Therapy in Dementia Patients: Findings from a Real-World Observational Study (2) 509–517
Pinessi, L., see Ferrari, R. (4) 1271–1278
Piorkowska, K., see Theunis, C. (2) 585–599
Pitkälä, K., see Kallio, E.-L. (4) 1349–1372
Plana, E., see Tell-Marti, G. (3) 1065–1074
Polcher, A., I. Frommann, A. Koppara, S. Wolfsgruber, F. Jessen and M. Wagner, Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment (3) 1185–1196
Potkin, S.G., see Doran, E. (2) 459–470
Potrony, M., see Tell-Marti, G. (3) 1065–1074
Prasad, V., see Apostolova, I. (1) 197–204
Prins, N.D., see Van Mierlo, L.D. (1) 249–259
Puig, S., see Tell-Marti, G. (3) 1065–1074
Puig-Butille, J.A., see Tell-Marti, G. (3) 1065–1074
Putignano, D., see Gareri, P. (2) 557–565
Putignano, S., see Gareri, P. (2) 557–565
Qiu, W.Q., see Mohamed, L.A. (3) 1087–1099
Qiu, W.Q., see Wang, E. (1) 47–61
Querfurth, H.W., see Lee, H.-K. (3) 1015–1036
Raffo, A., see Loewenstein, D.A. (3) 1119–1126
Raghavendra, C.S., see Amen, D.G. (1) 261–273
Raina, P., see Fenesi, B. (1) 297–303
Rainero, I., see Ferrari, R. (4) 1271–1278
Raji, C.A., see Amen, D.G. (1) 261–273
Rao, E.R., see Liu, P. (2) 743–761
Rasgon, N., see Sabbagh, M.N. (2) 441–446
Rathore, N., see Haddick, P.C.G. (3) 1037–1054
Rauchs, G., see Gaubert, M. (2) 717–731
Raux, M., see Zerah, L. (1) 145–156
Rea, R., see Carotenuto, A. (2) 805–815
Reddy, P., see Shukla, V. (1) 335–349
Reichl, J.H., see Liu, P. (2) 743–761
Reijmer, Y.D., see Valenti, R. (4) 1223–1227
Reinhardt, S., see Brandscheid, C. (2) 775–788
Remes, A.M., see Suhonen, N.-M. (4) 1241–1251
Reuter, M., see Kunz, L. (3) 1135–1144
Riant, F., see Sellal, F. (1) 37–46
Ricard-Blum, S., see Salza, R. (3) 991–1005
Ricci, G., see Carotenuto, A. (2) 805–815
Richards, D., see Sabbagh, M.N. (2) 441–446
Ricordi, C., see Squitti, R. (3) 1055–1064
Rietschel, M., see Khan, W. (3) 1159–1174
Riley, G., see Valenti, R. (4) 1223–1227
Rimondini, R., see Persson, T. (2) 601–617
Riou, B., see Zerah, L. (1) 145–156
Rissman, R.A., see Sokolow, S. (1) 229–237
Roberts, A., see Apostolova, I. (1) 197–204
Roffredo, L., see Monacelli, F. (2) 519–527
Rognoni, T., see Matías-Guiu, J.A. (2) 733–742
Romano, C., see Stoccoro, A. (4) 1451–1457
Ronowska, A., see Zyśk, M. (3) 1145–1158
Rosand, J., see Sellal, F. (1) 37–46
Rosenberg, P.B., see Ismail, Z. (3) 929–938
Rossi, G., see Ferrari, R. (4) 1271–1278
Rotter, J.I., see Sokolow, S. (1) 229–237
Rousseau, S., see Sellal, F. (1) 37–46
Rovelet-Lecrux, A., see Sellal, F. (1) 37–46
Rowe, C.C., see Sabbagh, M.N. (2) 441–446
Rozemuller, A.J., see Louwersheimer, E. (1) 63–74
Rubin, L.H., see Sundermann, E.E. (3) 947–957
Rubino, E., see Ferrari, R. (4) 1271–1278
Rubio-Rodrigo, M., see Persson, T. (2) 601–617
Ruggiero, C., see Boccardi, V. (1) 239–248
Sabbagh, M.N., B. Schäuble, K. Anand, D. Richards, S. Murayama, H. Akatsu, M. Takao, C.C. Rowe, C.L. Masters, H. Barthel, H.-J. Gertz, O. Peters, N. Rasgon, A. Jovalekic, O. Sabri, W.J. Schulz-Schaeffer and J. Seibyl, Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer’s Disease (2) 441–446
Sabri, O., see Sabbagh, M.N. (2) 441–446
Sager, M.A., see Law, L.L. (1) 351–359
Saji, N., see Sugimoto, T. (2) 567–574
Saka, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Sakowicz-Burkiewicz, M., see Zyśk, M. (3) 1145–1158
Sakurai, T., see Kamikubo, Y. (2) 641–653
Sakurai, T., see Sugimoto, T. (2) 567–574
Salluzzo, M.G., see Stoccoro, A. (4) 1451–1457
Salvadori, N., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Salza, R., C. Lethias and S. Ricard-Blum, The Multimerization State of the Amyloid-β42 Peptide (Aβ42) Governs its Interaction Network with the Extracellular Matrix (3) 991–1005
Sánchez-Muniz, F.J., see González-Muñoz, M.J. (3) 917–927
Sanchez-Valle, R., see Tell-Marti, G. (3) 1065–1074
Sanchez-Valle, R., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Sandebring-Matton, A., see Persson, T. (2) 601–617
Santamaria, F., see Gareri, P. (2) 557–565
Santana, I., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Scarpini, E., see Ferrari, R. (4) 1271–1278
Scarpini, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Schäfer, K.-H., see Brandscheid, C. (2) 775–788
Schäuble, B., see Sabbagh, M.N. (2) 441–446
Schellenberg, G.D., see Haddick, P.C.G. (3) 1037–1054
Scheltens, P., see Louwersheimer, E. (1) 63–74
Scheltens, P., see Slot, R.E.R. (2) 687–697
Scheltens, P., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Schneider, J., see Yarchoan, M. (2) 699–706
Schneider, J.A., see Yu, L. (4) 1485–1493
Schott, J.M., see Toombs, J. (3) 885–891
Schreurs, B.G., see Brooks, S.W. (1) 185–196
Schuck, F., see Brandscheid, C. (2) 775–788
Schultz, S.A., see Law, L.L. (1) 351–359
Schulz-Schaeffer, W.J., see Sabbagh, M.N. (2) 441–446
Schumann, G., see Khan, W. (3) 1159–1174
Schweizer, T.A., see Hird, M.A. (2) 447–452
Schwiertz, A., see Brandscheid, C. (2) 775–788
Segkouli, S., see Zygouris, S. (2) 619–627
Seibyl, J., see Sabbagh, M.N. (2) 441–446
Seixas, A., see Agyemang, C. (1) 205–213
Selfe, T.K., see Innes, K.E. (3) 899–916
Sellal, F., D. Wallon, L. Martinez-Almoyna, C. Marelli, A. Dhar, H. Oesterlé, A. Rovelet-Lecrux, S. Rousseau, C.E. Kourkoulis, J. Rosand, Z.Y. DiPucchio, M. Frosch, C. Gombert, B. Audoin, M. Miné, F. Riant, T. Frebourg, D. Hannequin, D. Campion, S.M. Greenberg, E. Tournier-Lasserve and G. Nicolas, APP Mutations in Cerebral Amyloid Angiopathy with or without Cortical Calcifications: Report of Three Families and a Literature Review (1) 37–46
Seo, J., see Shukla, V. (1) 335–349
Seo, S.W., see Chang, K.J. (4) 1341–1348
Serpente, M., see Ferrari, R. (4) 1271–1278
Sha, L., see Wu, L. (3) 893–898
Shah, R.C., see Yarchoan, M. (2) 699–706
Shaw, L.M., see Timmers, M. (4) 1437–1449
Shellington, E., see Heath, M. (1) 167–183
Shen, L., L. Liao, C. Chen, Y. Guo, D. Song, Y. Wang, Y. Chen, K. Zhang, M. Ying, S. Li, Q. Liu and J. Ni, Proteomics Analysis of Blood Serums from Alzheimer’s Disease Patients Using iTRAQ Labeling Technology (1) 361–378
Shen, L., L. Liu and H.-F. Ji, Alzheimer’s Disease Histological and Behavioral Manifestations in Transgenic Mice Correlate with Specific Gut Microbiome State (1) 385–390
Shenhar-Tsarfaty, S., see Molad, J. (4) 1293–1299
Shi, L., see Jia, J. (4) 1495–1504
Shin, D.C., see Marmarelis, V.Z. (1) 89–105
Shine, J.M., see McKinnon, A.C. (4) 1373–1384
Shopin, L., see Molad, J. (4) 1293–1299
Shu, H., see Su, F. (2) 491–507
Shu, H., see Wang, Z. (1) 415–428
Shua-Haim, J.R., see Boada, M. (1) 129–143
Shukla, V., J. Seo, B.K. Binukumar, N.D. Amin, P. Reddy, P. Grant, S. Kuntz, S. Kesavapany, J. Steiner, S.K. Mishra, L.-H. Tsai and H.C. Pant, TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice (1) 335–349
Siciliano, G., see Stoccoro, A. (4) 1451–1457
Siegel, A.M., M.S. Barrett and M.T. Bhati, Deep Brain Stimulation for Alzheimer’s Disease: Ethical Challenges for Clinical Research (2) 429–436
Signori, A., see Monacelli, F. (2) 519–527
Sikkes, S.A.M., see Van Mierlo, L.D. (1) 249–259
Simmons, A., see Khan, W. (3) 1159–1174
Simonelli, I., see Squitti, R. (3) 1055–1064
Sims, R., see Morgan, A.R. (1) 25–36
Singleton, A., see Ferrari, R. (4) 1271–1278
Sistermans, E.A., see Louwersheimer, E. (1) 63–74
Slemmon, J., see Timmers, M. (4) 1437–1449
Slot, R.E.R., A.C. Van Harten, M.I. Kester, W. Jongbloed, F.H. Bouwman, C.E. Teunissen, P. Scheltens, R. Veerhuis and W.M. van der Flier, Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer’s Disease in Non-Demented Elderly (2) 687–697
Small, G.W., see Doran, E. (2) 459–470
Smirne, N., see Boccardi, V. (1) 239–248
Smith, E.E., see Ismail, Z. (3) 929–938
Smith, G.S., see Ismail, Z. (3) 929–938
Smits, M., see Meijboom, R. (2) 789–804
Smolka, M.N., see Khan, W. (3) 1159–1174
Soennesyn, H., see Bergland, A.K. (2) 575–584
Soininen, H., see Imtiaz, B. (2) 453–458
Soininen, H., see Khan, W. (3) 1159–1174
Soininen, H., see Suhonen, N.-M. (4) 1241–1251
Soininen, H., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Sokolow, S., X. Li, L. Chen, K.D. Taylor, J.I. Rotter, R.A. Rissman, P.S. Aisen and L.G. Apostolova, Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment (1) 229–237
Solomon, A., see Imtiaz, B. (2) 453–458
Solomon, J., see Glozman, T. (1) 287–295
Son, S.J., see Chang, K.J. (4) 1341–1348
Song, D., see Shen, L. (1) 361–378
Song, N., see Tan, L. (2) 629–640
Song, Y.-Q., see Lin, T.-S. (3) 959–976
Soriano, E., see Gomez-Ramos, A. (3) 977–990
Spenger, C., see Khan, W. (3) 1159–1174
Squitti, R., A.J. Mendez, I. Simonelli and C. Ricordi, Diabetes and Alzheimer’s Disease: Can Elevated Free Copper Predict the Risk of the Disease? (3) 1055–1064
Srinivasan, K., see Haddick, P.C.G. (3) 1037–1054
Ståhlbom, A.K., see Li, X. (1) 327–334
Stechl, E., see Apostolova, I. (1) 197–204
Stein, J.H., see Law, L.L. (1) 351–359
Steiner, J., see Shukla, V. (1) 335–349
Steinhagen-Thiessen, E., see Apostolova, I. (1) 197–204
Steketee, R.M.E., see Meijboom, R. (2) 789–804
Stoccoro, A., P. Tannorella, M.G. Salluzzo, R. Ferri, C. Romano, B. Nacmias, G. Siciliano, L. Migliore and F. Coppedè, The Methylenetetrahydrofolate Reductase C677T Polymorphism and Risk for Late-Onset Alzheimer’s disease: Further Evidence in an Italian Multicenter Study (4) 1451–1457
Streffer, J.R., see Timmers, M. (4) 1437–1449
Ströhle, A., see Khan, W. (3) 1159–1174
Stronks, K., see Agyemang, C. (1) 205–213
Su, F., H. Shu, Q. Ye, C. Xie, B. Yuan, Z. Zhang and F. Bai, Integration of Multilocus Genetic Risk into the Default Mode Network Longitudinal Trajectory during the Alzheimer’s Disease Process (2) 491–507
Sugimoto, H., see Kotani, R. (2) 529–542
Sugimoto, T., M. Yoshida, R. Ono, S. Murata, N. Saji, S. Niida, K. Toba and T. Sakurai, Frontal Lobe Function Correlates with One-Year Incidence of Urinary Incontinence in Elderly with Alzheimer Disease (2) 567–574
Suhonen, N.-M., I. Hallikainen, T. Hänninen, J. Jokelainen, J. Krüger, A. Hall, M. Pikkarainen, H. Soininen and A.M. Remes, The Modified Frontal Behavioral Inventory (FBI-mod) for Patients with Frontotemporal Lobar Degeneration, Alzheimer’s Disease, and Mild Cognitive Impairment (4) 1241–1251
Sultzer, D.L., see Ismail, Z. (3) 929–938
Sun, N., see Chen, J. (2) 471–489
Sun, S., see Tan, L. (2) 629–640
Sun, X., see Loewenstein, D.A. (3) 1119–1126
Sundermann, E.E., A. Biegon, L.H. Rubin, R.B. Lipton, S. Landau and P.M. Maki for the Alzheimer’s Disease Neuroimaging Initiative, Does the Female Advantage in Verbal Memory Contribute to Underestimating Alzheimer’s Disease Pathology in Women versus Men? (3) 947–957
Sundström, E., see Persson, T. (2) 601–617
Szűcs, A., see Horváth, A. (3) 1175–1183
Szutowicz, A., see Zyśk, M. (3) 1145–1158
Taddei, K., see Peters, K.E. (3) 1127–1133
Tagliavini, F., see Ferrari, R. (4) 1271–1278
Taipale, H., see Koponen, M. (1) 107–118
Taipale, H., see Lampela, P. (1) 119–128
Takada, A., see Kuriyama, N. (4) 1253–1262
Takao, M., see Sabbagh, M.N. (2) 441–446
Takasugi, N., see Kamikubo, Y. (2) 641–653
Takeda, K., see Kuriyama, N. (4) 1253–1262
Tamura, A., see Kuriyama, N. (4) 1253–1262
Tan, L., H. Yang, W. Pang, H. Li, W. Liu, S. Sun, N. Song, W. Zhang and Y. Jiang, Investigation on the Role of BDNF in the Benefits of Blueberry Extracts for the Improvement of Learning and Memory in Alzheimer’s Disease Mouse Model (2) 629–640
Tang, Y., see Jia, J. (4) 1495–1504
Tannorella, P., see Stoccoro, A. (4) 1451–1457
Tanskanen, A., see Koponen, M. (1) 107–118
Tanskanen, A., see Lampela, P. (1) 119–128
Tapias, V., see Fitz, N.F. (3) 1075–1085
Tarducci, R., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Tárraga, L., see Boada, M. (1) 129–143
Tarumi, T., see Marmarelis, V.Z. (1) 89–105
Taylor, K.D., see Sokolow, S. (1) 229–237
Tell-Marti, G., J.A. Puig-Butille, M. Potrony, E. Plana, C. Badenas, A. Antonell, R. Sanchez-Valle, J.L. Molinuevo, A. Lleó, D. Alcolea, J. Fortea, R. Fernández-Santiago, J. Clarimón, A. Lladó and S. Puig, A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer’s Disease Risk (3) 1065–1074
Terpening, Z., see McKinnon, A.C. (4) 1373–1384
Tesseur, I., see Timmers, M. (4) 1437–1449
Teunissen, C., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Teunissen, C.E., see Slot, R.E.R. (2) 687–697
Theunis, C., O. Adolfsson, N. Crespo-Biel, K. Piorkowska, M. Pihlgren, D.T. Hickman, V. Gafner, P. Borghgraef, H. Devijver, A. Pfeifer, F. Van Leuven and A. Muhs, Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope (2) 585–599
Thevarkunnel, S., see Borghys, H. (2) 763–774
Thordardottir, S., see Li, X. (1) 327–334
Thygesen, L.C., L.N. Gimsing, A. Bautz, N.C. Hvidt and C. Johansen, Chronic Neurodegenerative Illnesses and Epilepsy in Danish Adventists and Baptists: A Nationwide Cohort Study (4) 1429–1435
Tiihonen, J., see Koponen, M. (1) 107–118
Tiihonen, J., see Lampela, P. (1) 119–128
Timmers, M., S. Barão, B. Van Broeck, I. Tesseur, J. Slemmon, K. De Waepenaert, J. Bogert, L.M. Shaw, S. Engelborghs, D. Moechars, M. Mercken, L. Van Nueten, L. Tritsmans, B. de Strooper and J.R. Streffer BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants (4) 1437–1449
Titheridge, S., see Heath, M. (1) 167–183
Toba, K., see Sugimoto, T. (2) 567–574
Tokuda, T., see Kuriyama, N. (4) 1253–1262
Tolppanen, A.M., see Imtiaz, B. (2) 453–458
Tolppanen, A.-M., see Koponen, M. (1) 107–118
Tolppanen, A.-M., see Lampela, P. (1) 119–128
Toombs, J., M.S. Foiani, R.W. Paterson, A. Heslegrave, S. Wray, J.M. Schott, N.C. Fox, M.P. Lunn, K. Blennow and H. Zetterberg, Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration (3) 885–891
Torkilsen, C.G., see Ebel, D.L. (3) 1197–1211
Torres, M., see Boada, M. (1) 129–143
Totoiu, M., see Doran, E. (2) 459–470
Touchard, S., see Morgan, A.R. (1) 25–36
Tourette, C., see Zerah, L. (1) 145–156
Tournier-Lasserve, E., see Sellal, F. (1) 37–46
Traini, E., see Carotenuto, A. (2) 805–815
Tremblay, S., see Castellano, C.-A. (4) 1459–1468
Tritsmans, L., see Timmers, M. (4) 1437–1449
Tsai, H.-J., see Lin, T.-S. (3) 959–976
Tsai, L.-H., see Shukla, V. (1) 335–349
Tsolaki, M., see Khan, W. (3) 1159–1174
Tsolaki, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Tsolaki, M., see Zygouris, S. (2) 619–627
Tucker, D., see Lu, Y. (4) 1469–1484
Tufts, E., see Last, N. (1) 275–286
Tzovaras, D., see Zygouris, S. (2) 619–627
Urano, Y., see Kotani, R. (2) 529–542
Urbani, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Vaartjes, I., see Agyemang, C. (1) 205–213
Valcarcel, B., see Ho, L. (1) 305–315
Valenti, R., A. Charidimou, L. Xiong, G. Boulouis, P. Fotiadis, A. Ayres, G. Riley, H.J. Kuijf, Y.D. Reijmer, L. Pantoni, M.E. Gurol, S. Davidsdottir, S.M. Greenberg and A. Viswanathan, Visuospatial Functioning in Cerebral Amyloid Angiopathy: A Pilot Study (4) 1223–1227
Valles-Salgado, M., see Matías-Guiu, J.A. (2) 733–742
Van Broeck, B., see Borghys, H. (2) 763–774
Van Broeck, B., see Timmers, M. (4) 1437–1449
van de Vorst, I.E., see Agyemang, C. (1) 205–213
van der Brug, M., see Haddick, P.C.G. (3) 1037–1054
Van der Flier, W.M., see Louwersheimer, E. (1) 63–74
van der Flier, W.M., see Slot, R.E.R. (2) 687–697
Van der Flier, W.M., see Van Mierlo, L.D. (1) 249–259
van der Lugt, A., see Meijboom, R. (2) 789–804
van Duijn, C.M., see Louwersheimer, E. (1) 63–74
Van Harten, A.C., see Slot, R.E.R. (2) 687–697
Van Hout, H.P.J., see Van Mierlo, L.D. (1) 249–259
Van Leuven, F., see Theunis, C. (2) 585–599
Van Mierlo, L.D., H. Wouters, S.A.M. Sikkes, W.M. Van der Flier, N.D. Prins, J.A.E. Bremer, T. Koene and H.P.J. Van Hout, Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests (1) 249–259
Van Nueten, L., see Timmers, M. (4) 1437–1449
van Swieten, J.C., see Louwersheimer, E. (1) 63–74
van Swieten, J.C., see Meijboom, R. (2) 789–804
van Waalwijk van Doorn, L.J.C., J.D. Gispert, H.B. Kuiperij, J.A.H.R. Claassen, A. Arighi, I. Baldeiras, K. Blennow, M. Bozzali, M. Castelo-Branco, E. Cavedo, D.D. Emek-Savaş, E. Eren, P. Eusebi, L. Farotti, C. Fenoglio, J.F. Ormaechea, Y. Freund-Levi, G.B. Frisoni, D. Galimberti, S. Genc, V. Greco, H. Hampel, S.-K. Herukka, Y. Liu, A. Lladó, A. Lleó, F.M. Nobili, K.K. Oguz, L. Parnetti, J. Pereira, A. Picco, M. Pikkarainen, C.R. de Oliveira, E. Saka, N. Salvadori, R. Sanchez-Valle, I. Santana, E. Scarpini, P. Scheltens, H. Soininen, R. Tarducci, C. Teunissen, M. Tsolaki, A. Urbani, E. Vilaplana, P.J. Visser, A.K. Wallin, G. Yener, J.L. Molinuevo, O. Meulenbroek and M.M. Verbeek, Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer’s Disease Patients and Controls after Correction for Ventricular Volumes (2) 543–555
Vasiliev, A.V., see Dashinimaev, E.B. (2) 835–847
Vassar, R., see Liu, P. (2) 743–761
Veerhuis, R., see Slot, R.E.R. (2) 687–697
Vellas, B., see Khan, W. (3) 1159–1174
Verbeek, M.M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Verny, M., see Zerah, L. (1) 145–156
Vesely, K.A., see Hird, M.A. (2) 447–452
Vilaplana, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Villain, N., see Gaubert, M. (2) 717–731
Villemagne, V.L., see Khan, W. (3) 1159–1174
Visser, P.J., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Viswanathan, A., see Valenti, R. (4) 1223–1227
Vorotelyak, E.A., see Dashinimaev, E.B. (2) 835–847
Votis, K., see Zygouris, S. (2) 619–627
Wagner, M., see Polcher, A. (3) 1185–1196
Wahlund, L.-O., see Khan, W. (3) 1159–1174
Wahlund, L.-O., see Li, X. (1) 327–334
Waldemar, G., see Nørgaard, A. (2) 707–716
Wallack, M., see Wang, E. (1) 47–61
Wallin, A.K., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Wallon, D., see Sellal, F. (1) 37–46
Wang, E., H. Zhu, X. Wang, A.C. Gower, M. Wallack, J.K. Blusztajn, N. Kowall and W.Q. Qiu, Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer’s Disease Mouse Model (1) 47–61
Wang, E., see Mohamed, L.A. (3) 1087–1099
Wang, H., X. Hong and Y. Wang, Mitochondrial Repair Effects of Oxygen Treatment on Alzheimer’s Disease Model Mice Revealed by Quantitative Proteomics (3) 875–883
Wang, L., see Li, L. (4) 1403–1417
Wang, Q., W.-X. Li, S.-X. Dai, Y.-C. Guo, F.-F. Han, J.-J. Zheng, G.-H. Li and J.-F. Huang, Meta-Analysis of Parkinson’s Disease and Alzheimer’s Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes (4) 1525–1539
Wang, R., see Lu, Y. (4) 1469–1484
Wang, X., see Li, L. (4) 1403–1417
Wang, X., see N’Songo, A. (4) 1215–1222
Wang, X., see Wang, E. (1) 47–61
Wang, X., see Wu, L. (3) 893–898
Wang, Y., see Shen, L. (1) 361–378
Wang, Y., see Wang, H. (3) 875–883
Wang, Z., Z. Dai, H. Shu, D. Liu, Q. Guo, Y. He and Z. Zhang, Cortical Thickness and Microstructural White Matter Changes Detect Amnestic Mild Cognitive Impairment (1) 415–428
Wangmo, T., see Ienca, M. (4) 1301–1340
Watanabe, I., see Kuriyama, N. (4) 1253–1262
Watanabe, Y., see Kuriyama, N. (4) 1253–1262
Watts, R.J., see Haddick, P.C.G. (3) 1037–1054
Wei, C., see Jia, J. (4) 1495–1504
Weiss, M.M., see Louwersheimer, E. (1) 63–74
Westman, E., see Khan, W. (3) 1159–1174
Westman, E., see Li, X. (1) 327–334
Willette, A.A., see McLimans, K.E. (1) 403–413
Williams, J., see Morgan, A.R. (1) 25–36
Williams, S.C.R., see Khan, W. (3) 1159–1174
Wilson, R.S., see Yarchoan, M. (2) 699–706
Wilson, R.S., see Yu, L. (4) 1485–1493
Wittwer, J., see Pimouguet, C. (2) 509–517
Wolfsgruber, S., see Polcher, A. (3) 1185–1196
Wood, J.P.M., see Chidlow, G. (2) 655–675
Wouters, H., see Van Mierlo, L.D. (1) 249–259
Wray, S., see Toombs, J. (3) 885–891
Wright, C., see Loewenstein, D.A. (3) 1119–1126
Wright, C.E., see Betrie, A.H. (2) 849–860
Wu, L., J. Liu, L. Sha, X. Wang, J. Li, J. Dong and J. Jia, Sporadic Cases with Novel Mutations and Pedigree in Hereditary Leukoencephalopathy with Axonal Spheroids (3) 893–898
Xiao, C., see Chen, J. (2) 471–489
Xie, B., Y. Xu, Z. Liu, W. Liu, L. Jiang, R. Zhang, D. Cui, Q. Zhang and S. Xu, Elevation of Peripheral BDNF Promoter Methylation Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer’s Disease: A 5-Year Longitudinal Study (1) 391–401
Xie, C., see Su, F. (2) 491–507
Xiong, L., see Valenti, R. (4) 1223–1227
Xu, J., see Hu, C. (4) 1263–1269
Xu, S., see Li, L. (4) 1403–1417
Xu, S., see Xie, B. (1) 391–401
Xu, X., see Hu, C. (4) 1263–1269
Xu, Y., see Xie, B. (1) 391–401
Yamada, K., see Kuriyama, N. (4) 1253–1262
Yamasaki, S., see Nakanishi, M. (2) 817–824
Yang, H., see Tan, L. (2) 629–640
Yarchoan, M., B.D. James, R.C. Shah, Z. Arvanitakis, R.S. Wilson, J. Schneider, D.A. Bennett and S.E. Arnold, Association of Cancer History with Alzheimer’s Disease Dementia and Neuropathology (2) 699–706
Ye, Q., see Su, F. (2) 491–507
Yener, G., see van Waalwijk van Doorn, L.J.C. (2) 543–555
Ying, M., see Shen, L. (1) 361–378
Yoshida, M., see Sugimoto, T. (2) 567–574
Younesi, E., see Emon, M.A.E.K. (2) 677–686
Younkin, S.G., see N’Songo, A. (4) 1215–1222
Yu, L., R.S. Wilson, J.A. Schneider, D.A. Bennett and P.A. Boyle, Financial and Health Literacy Predict Incident Alzheimer’s Disease Dementia and Pathology (4) 1485–1493
Yuan, B., see Su, F. (2) 491–507
Zahs, K.R., see Liu, P. (2) 743–761
Zeng, L., see Hu, C. (4) 1263–1269
Zerah, L., J. Cohen-Bittan, M. Raux, A. Meziere, C. Tourette, C. Neri, M. Verny, B. Riou, F. Khiami and J. Boddaert, Association between Cognitive Status before Surgery and Outcomes in Elderly Patients with Hip Fracture in a Dedicated Orthogeriatric Care Pathway (1) 145–156
Zetterberg, H., see Toombs, J. (3) 885–891
Zhan, L., see Chen, J. (2) 471–489
Zhang, K., see Shen, L. (1) 361–378
Zhang, Q., see Lu, Y. (4) 1469–1484
Zhang, Q., see Xie, B. (1) 391–401
Zhang, R., see Marmarelis, V.Z. (1) 89–105
Zhang, R., see Xie, B. (1) 391–401
Zhang, W., see Tan, L. (2) 629–640
Zhang, Z., see Su, F. (2) 491–507
Zhang, Z., see Wang, Z. (1) 415–428
Zhao, X., see Li, L. (4) 1403–1417
Zheng, J.-J., see Wang, Q. (4) 1525–1539
Zhou, A., see Jia, J. (4) 1495–1504
Zhu, H., see Mohamed, L.A. (3) 1087–1099
Zhu, H., see Wang, E. (1) 47–61
Zygouris, S., K. Ntovas, D. Giakoumis, K. Votis, S. Doumpoulakis, S. Segkouli, C. Karagiannidis, D. Tzovaras and M. Tsolaki, A Preliminary Study on the Feasibility of Using a Virtual Reality Cognitive Training Application for Remote Detection of Mild Cognitive Impairment (2) 619–627
Zyśk, M., H. Bielarczyk, S. Gul-Hinc, A. Dyś, B. Gapys, A. Ronowska, M. Sakowicz-Burkiewicz and A. Szutowicz, Phenotype-Dependent Interactions between N-acetyl-L-Aspartate and Acetyl-CoA in Septal SN56 Cholinergic Cells Exposed to an Excess of Zinc (3) 1145–1158
